pharmaphorum

JANUARY 24, 2022

In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease. pharmaphorum caught up with AZ’s Joris Silon to discuss unmet needs in the condition. “Many times, I have talked to nephrologists who take care of patients with chronic kidney disease in the later stages, and they have a very simple message – and that is, if we really want to do something for these patients then we need to intervene earlier,” says Joris Silon, se

119

119

Outsourcing Pharma

JANUARY 24, 2022

The CRO's work with La Jolla Institute for Immunology, centered on a unique mouse model, is intended to increase understanding of how the COVID-19 virus operates.

99

99

pharmaphorum

JANUARY 24, 2022

A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.

Cerner 111

Cerner 111

Fierce Healthcare

JANUARY 24, 2022

From full-page newspaper ads to press events, hospitals say their pandemic pleas are reaching the public. dmuoio. Mon, 01/24/2022 - 15:20.

Hospitals 105

Hospitals 105

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JANUARY 24, 2022

With healthcare systems around the world labouring under the strain of dealing with the Omicron wave of COVID-19 infections, attention is already turning to a new sub-variant that is starting to emerge in some countries, including the UK, India and Denmark. Dubbed BA.2, the sub-variant of Omicron (BA.1) hasn’t been classed as a variant of concern (VoC) by the World Health Organisation (WHO) yet, but is under investigation by the UK’s Health Security Agency with more than 400 cases detected

Vaccines 98

Vaccines Hospitals 98

Fierce Healthcare

JANUARY 24, 2022

Novant Health teams up with Aidoc to expedite imaging in its emergency departments. rtorrence. Mon, 01/24/2022 - 10:53.

110

110

Fierce Healthcare

JANUARY 24, 2022

WTW survey: Employers see workers' mental well-being as a top priority this year. pminemyer. Mon, 01/24/2022 - 16:14.

110

110

Birth Control Pharmacist

JANUARY 24, 2022

Pharmacists in the community setting may soon have the opportunity to ease access to medication abortion in the United States. In the coming months, mifepristone (Mifeprex) is anticipated to have an updated Risk Evaluation and Mitigation Strategy (REMS) Program that allows dispensing through local brick-and-mortar and mail-order pharmacies. This change will integrate pharmacists into abortion care and bring them to the forefront of the national discussion about reproductive rights.

Mail-Order Pharmacies 52

Mail-Order Pharmacies FDA Patient Care 52

Fierce Healthcare

JANUARY 24, 2022

Senators want Medicare to reimburse at-home COVID-19 tests just like commercial insurers. rking. Mon, 01/24/2022 - 16:20.

Insurance 105

Insurance 105

pharmaphorum

JANUARY 24, 2022

After regulatory hold-ups in the US and Europe, Ipsen has claimed a confidence-boosting approval in Canada for palovarotene, a rare disease therapy acquired via its $1.3 billion takeover of Clementia Pharma in 2019. Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva (FOP), making it the first treatment for the ultra-rare genetic disorder.

FDA 52

FDA 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

JANUARY 24, 2022

ThirdEye brings mixed reality tech to first responders with Crozer Health partnership. rtorrence. Mon, 01/24/2022 - 18:27.

98

98

pharmaphorum

JANUARY 24, 2022

Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare. SMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference , taking place on the 14th and 15th March 2022 in London, UK. Chaired by: Darren Green, Director of Computational Chemistry, GSK. Sponsored by: Optibrium. With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest.

Compounding 52

Compounding 52

Fierce Healthcare

JANUARY 24, 2022

Providers hope Congress agrees to sequester relief in must-pass spending package. rking. Mon, 01/24/2022 - 14:24.

Packaging 98

Packaging 98

pharmaphorum

JANUARY 24, 2022

SMi’s 6th Annual. Highly Potent Active Pharmaceutical Ingredients. 9th and 10th May 2022. London, UK. www.highlypotentapi.com/pharmaphorum. Ensuring Risk-Based, Safety-Driven, High-Quality Operation. The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and m

52

52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

JANUARY 24, 2022

Cigna expands RecoveryOne partnership to Medicare Advantage members. pminemyer. Mon, 01/24/2022 - 12:56.

98

98

pharmaphorum

JANUARY 24, 2022

NICE has recommended extending funding via the NHS for AstraZeneca’s elevated potassium therapy Lokelma in new guidance, making it easier to receive the drug outside hospital settings. The new guidance means adults living with persistently high potassium levels in the blood – a condition known as hyperkalaemia – can now get repeat prescriptions for Lokelma (sodium zirconium cyclosilicate) in the community.

Hospitals 52

Hospitals FDA 52

Outsourcing Pharma

JANUARY 24, 2022

Experts from global professional services outfit Alvarez and Marsal outline challenges created or exacerbated by COVID-19 and insights into potential solutions.

52

52

Pharma Times

JANUARY 24, 2022

The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed with COPD.

41

41

pharmaphorum

JANUARY 24, 2022

The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with COVID-19, extending the uses of the drug. The green light means that intravenously-administered Veklury (remdesivir) is another option for non-hospitalised patients with mild-to-moderate COVID-19 who are at high risk of progression to severe disease, alongside oral antivirals from Pfizer and Merck & Co.

FDA 98

FDA 98

Pharma Times

JANUARY 24, 2022

Beckley Psytech leads a new project focused on addressing psychiatric and neurological conditions through the use of psychedelic medicines.

40

40